Shanghai Hile Bio-tech (603718) - Net Assets
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has net assets worth CN¥936.02 Million CNY (≈ $136.97 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.25 Billion ≈ $182.76 Million USD) and total liabilities (CN¥312.90 Million ≈ $45.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shanghai Hile Bio-tech tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥936.02 Million |
| % of Total Assets | 74.95% |
| Annual Growth Rate | 5.82% |
| 5-Year Change | -9.24% |
| 10-Year Change | -10.88% |
| Growth Volatility | 25.53 |
Shanghai Hile Bio-tech - Net Assets Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Shanghai Hile Bio-tech to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual net assets of Shanghai Hile Bio-tech from 2011 to 2025. For live valuation and market cap data, see Shanghai Hile Bio-tech market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥895.97 Million ≈ $131.11 Million |
-47.39% |
| 2024-12-31 | CN¥1.70 Billion ≈ $249.23 Million |
+44.98% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
+5.74% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.57 Million |
+12.54% |
| 2021-12-31 | CN¥987.19 Million ≈ $144.46 Million |
+2.60% |
| 2020-12-31 | CN¥962.20 Million ≈ $140.80 Million |
-3.06% |
| 2019-12-31 | CN¥992.57 Million ≈ $145.24 Million |
-3.24% |
| 2018-12-31 | CN¥1.03 Billion ≈ $150.10 Million |
-4.57% |
| 2017-12-31 | CN¥1.07 Billion ≈ $157.29 Million |
+6.92% |
| 2016-12-31 | CN¥1.01 Billion ≈ $147.11 Million |
+4.36% |
| 2015-12-31 | CN¥963.31 Million ≈ $140.96 Million |
+72.48% |
| 2014-12-31 | CN¥558.50 Million ≈ $81.73 Million |
+11.55% |
| 2013-12-31 | CN¥500.66 Million ≈ $73.26 Million |
+7.01% |
| 2012-12-31 | CN¥467.89 Million ≈ $68.47 Million |
+15.32% |
| 2011-12-31 | CN¥405.74 Million ≈ $59.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Hile Bio-tech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥28.29 Million | 3.21% |
| Other Components | CN¥853.75 Million | 96.79% |
| Total Equity | CN¥882.04 Million | 100.00% |
Shanghai Hile Bio-tech Competitors by Market Cap
The table below lists competitors of Shanghai Hile Bio-tech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NICE Holdings Co. Ltd
KO:034310
|
$274.84 Million |
|
Blue Foundry Bancorp
NASDAQ:BLFY
|
$274.88 Million |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
$275.00 Million |
|
Veedol Corporation Limited
NSE:VEEDOL
|
$275.03 Million |
|
Real Matters Inc
TO:REAL
|
$274.60 Million |
|
K&F Growth Acquisition Corp. II Unit
NASDAQ:KFIIU
|
$274.56 Million |
|
Chunbo Co. Ltd
KQ:278280
|
$274.56 Million |
|
Te Chang Construction Co Ltd
TWO:5511
|
$274.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Hile Bio-tech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,560,478,382 to 882,040,945, a change of -678,437,437 (-43.5%).
- Net loss of 311,436,623 reduced equity.
- Dividend payments of 122,262,311 reduced retained earnings.
- Other factors decreased equity by 244,738,504.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-311.44 Million | -35.31% |
| Dividends Paid | CN¥122.26 Million | -13.86% |
| Other Changes | CN¥-244.74 Million | -27.75% |
| Total Change | CN¥- | -43.48% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Hile Bio-tech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.81x to 2.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.76 | CN¥2.88 | x |
| 2012-12-31 | CN¥0.97 | CN¥2.88 | x |
| 2013-12-31 | CN¥1.01 | CN¥2.88 | x |
| 2014-12-31 | CN¥1.13 | CN¥2.88 | x |
| 2015-12-31 | CN¥1.65 | CN¥2.88 | x |
| 2016-12-31 | CN¥1.49 | CN¥2.88 | x |
| 2017-12-31 | CN¥1.66 | CN¥2.88 | x |
| 2018-12-31 | CN¥1.64 | CN¥2.88 | x |
| 2019-12-31 | CN¥1.75 | CN¥2.88 | x |
| 2020-12-31 | CN¥1.19 | CN¥2.88 | x |
| 2021-12-31 | CN¥1.49 | CN¥2.88 | x |
| 2022-12-31 | CN¥1.78 | CN¥2.88 | x |
| 2023-12-31 | CN¥1.94 | CN¥2.88 | x |
| 2024-12-31 | CN¥2.37 | CN¥2.88 | x |
| 2025-12-31 | CN¥1.35 | CN¥2.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Hile Bio-tech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -165.77%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.28x
- Recent ROE (-35.31%) is below the historical average (8.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 26.44% | 41.24% | 0.52x | 1.24x | CN¥66.70 Million |
| 2012 | 24.05% | 36.21% | 0.55x | 1.20x | CN¥65.76 Million |
| 2013 | 24.34% | 37.26% | 0.53x | 1.23x | CN¥69.99 Million |
| 2014 | 18.50% | 35.48% | 0.44x | 1.20x | CN¥46.50 Million |
| 2015 | 10.32% | 30.14% | 0.26x | 1.34x | CN¥3.00 Million |
| 2016 | 8.71% | 24.91% | 0.23x | 1.51x | CN¥-12.62 Million |
| 2017 | 10.63% | 37.46% | 0.19x | 1.50x | CN¥6.78 Million |
| 2018 | 2.02% | 8.37% | 0.15x | 1.66x | CN¥-84.25 Million |
| 2019 | 1.15% | 4.37% | 0.16x | 1.60x | CN¥-93.93 Million |
| 2020 | 0.84% | 3.44% | 0.15x | 1.69x | CN¥-96.91 Million |
| 2021 | 5.36% | 15.51% | 0.19x | 1.83x | CN¥-46.70 Million |
| 2022 | 10.66% | 40.54% | 0.20x | 1.33x | CN¥7.57 Million |
| 2023 | 5.17% | 26.12% | 0.15x | 1.36x | CN¥-58.83 Million |
| 2024 | 10.97% | 63.16% | 0.15x | 1.17x | CN¥15.13 Million |
| 2025 | -35.31% | -165.77% | 0.17x | 1.28x | CN¥-399.64 Million |
Industry Comparison
This section compares Shanghai Hile Bio-tech's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,212,589,599
- Average return on equity (ROE) among peers: 2.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Hile Bio-tech (603718) | CN¥936.02 Million | 26.44% | 0.33x | $274.74 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.64 Billion |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more